VEGFA and neoplasm: In 2023, researchers discovered that treatment with VEGF-targeted agents such as sunitinib or bevacizumab restored ICAM-1 expression in endothelial cells, promoted leukocyte adhesion and infiltration, and generated a pro-inflammatory tumor milieu.